Sep 23, 2026
Editas stock raised to Buy at Guggenheim (EDIT:NASDAQ)
Guggenheim has upgraded Editas Medicine (EDIT) stock to Buy from Neutral. The upgrade is based on the potential of the company's hyperlipidemia therapy, EDIT-401, which offers a novel gene editing approach for treating severely high blood cholesterol. Editas is currently preparing to advance this therapy.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 23, 2026
Guggenheim Upgrades Editas Medicine to Buy From Neutral, Price Target is $5
Guggenheim has upgraded Editas Medicine (EDIT) to a "Buy" rating from "Neutral," setting a new price target of $5. The article mentions that Editas Medicine currently has an average analyst rating of overweight with a mean price target of $4.88. Access to the full report requires a premium subscription.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Sep 12, 2026
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine plans to begin patient dosing in 2026 for its lead gene-editing therapy, EDIT-401, targeting high LDL cholesterol. This in vivo CRISPR therapy aims to increase LDL receptor production, with non-human primate studies showing a 90% reduction in LDL cholesterol. The company, which had $212 million in cash as of Q2, expects initial safety data in Q1 2027 and broader results later that year, anticipating funding operations into the second half of 2028.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish